Compare DexCom, Inc. (DXCM) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Honeywell International Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Honeywell International Inc trades at $206.77 (market cap $65.48B). The key difference: Honeywell International Inc is far larger — about 2.1× DexCom, Inc.'s market cap, and Honeywell International Inc pays a 1.36% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Honeywell International Inc for 90 Days on average.
| DXCM | HON | |
|---|---|---|
Market Cap | $31.86B | $65.48B |
Volume | 3,607,070 | 2,047,782 |
Sector | Health | Industrials |
52-Week High | $92.34 | $248.79 |
52-Week Low | $54.84 | $188.14 |
Typical Hold Time | 62 Days | 90 Days |
Enterprise Value | $31.32B | $90.27B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 8 and robust profitability margins. The company has beaten earnings estimates for three consecutive quarters and maintains a 66.7% analyst buy rating with a $259.25 consensus price target. Recent corporate developments include a $300 million refinery project win and quarterly dividend payments of $0.70 per share.
The outlook remains positive given HON's earnings momentum and strategic focus on automation post-spinoff, though technical weakness and rising debt-to-asset ratios pose near-term risks. Wall Street optimism is supported by strong profitability metrics and recent contract wins, while investors should monitor execution of the company's transformation strategy and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
